Form 4: Generation Bio Director Sells All Shares Post-Merger

Generation Bio Co. Director Ronald Cooper reported the disposition of all his common stock and stock options following the company's merger with XOMA Royalty Corporation, effective February 9, 2026.

Summary

• Ronald Cooper, a Director of Generation Bio Co. (GBIO), disposed of all his common stock and derivative securities (stock options) in the company.
• The transactions occurred on February 9, 2026, which was the effective date of the merger between Generation Bio Co. and XOMA Royalty Corporation.
• Under the merger agreement, Generation Bio Co. shareholders received $4.2913 per share in cash, plus one non-tradeable contingent value right (CVR) per share.
• The CVR has an estimated maximum contingent consideration amount of $25.01 per CVR.
• In-the-money stock options (exercise price less than $4.2913) were cancelled and converted into cash, calculated as the difference between the cash amount and the exercise price, multiplied by the number of shares.
• For example, 3,000 options with an exercise price of $3.874 were converted into cash, yielding $0.4173 per share, totaling $1,251.90.
• Out-of-the-money stock options (exercise price equal to or greater than $4.2913) were automatically cancelled for no consideration.
• Following these transactions, Ronald Cooper beneficially owns 0 shares of common stock and 0 derivative securities in Generation Bio Co.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral post-merger regulatory filing. It reflects the finalization of a director's holdings following an acquisition, which was an expected outcome of the merger. The CVR introduces a speculative element for former shareholders.

Positives

• Shareholders of Generation Bio Co. received a cash payment of $4.2913 per share.
• Shareholders also received a non-tradeable contingent value right (CVR) per share, offering potential future payments with an estimated maximum of $25.01 per CVR.
• In-the-money stock options held by the director were converted into cash, providing a payout for those holdings.

Negatives

• Out-of-the-money stock options held by the director were cancelled for no consideration, resulting in a loss of potential value for those specific holdings.
• Generation Bio Co. ceased to be an independent publicly traded company, becoming a wholly-owned subsidiary of XOMA Royalty Corporation.

Risks

• The contingent value rights (CVRs) are non-tradeable, limiting liquidity for shareholders.
• The value of the CVRs is contingent upon future events and milestones, meaning the estimated maximum contingent consideration of $25.01 is not guaranteed and may not be realized.

Future Outlook

The future outlook for former Generation Bio Co. shareholders includes potential contingent payments from the non-tradeable CVRs, which are subject to specific terms and conditions outlined in the contingent value rights agreement.

Industry Context

StockSavvy.ai notes that the acquisition of smaller biotechnology companies by larger entities, often involving contingent value rights (CVRs), is a common strategy in the life sciences sector. This structure allows the acquiring company to mitigate risk by tying a portion of the acquisition price to the achievement of future development or commercial milestones, which is particularly relevant for early-stage assets with uncertain outcomes.

Comparison to Industry Standards

• The use of Contingent Value Rights (CVRs) in this merger aligns with common practices in the biotechnology and pharmaceutical industries for acquisitions where the target company's value is heavily dependent on future clinical or regulatory milestones.
• Similar CVR structures have been observed in acquisitions such as Sanofi's acquisition of Principia Biopharma or Bristol Myers Squibb's acquisition of MyoKardia, where a portion of the deal value was contingent on drug approval or sales targets.

Corporate Governance

Stakeholder Impact

• Shareholders: Received cash and CVRs for their shares, transitioning from equity holders in an independent public company to holders of cash and contingent rights.
• Employees (with stock options): Those with in-the-money options received cash payouts, while those with out-of-the-money options had them cancelled for no value.

Next Steps

• Former Generation Bio Co. shareholders will await potential future payments related to the contingent value rights (CVRs) based on the terms of the CVR agreement.

Key Dates

Keywords

Generation Bio Co., GBIO, XOMA Royalty Corporation, Merger, Acquisition, Contingent Value Right, CVR, Insider Transaction, Stock Options, Form 4